SINAPPS stands for Study of ImmuNology in Antibody Positive PsychosiS.
We are a research group formed of collaborating Universities in the UK, investigating the role of immunotherapy and autoimmune antibodies as a cause of psychosis.
Our group's research spans a number of universities and hospitals in England, but was founded by Researchers at the Universities of Oxford and Cambridge.
The Department of Psychiatry's Early Psychosis Research Group is the Oxford SINAPPS hub, headed by one of our PIs, Professor Belinda Lennox. This group manages the running of both our PPiP and Feasibility studies.
Cambridge Neuroscience is the second SINAPPS hub, where two of our PIs, Professors Peter Jones and Alasdair Coles, are based. This group co-manages the running of the SINAPPS Clinical Trial study, and is a recruitment site for PPiP.
Dr Michael Zandi is one of our investigators and a consultant neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London.